X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs PANACEA BIOTECH - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA PANACEA BIOTECH GSK PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 67.4 -21.8 - View Chart
P/BV x 11.8 3.1 387.1% View Chart
Dividend Yield % 1.1 0.0 -  

Financials

 GSK PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
PANACEA BIOTECH
Mar-14
GSK PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,838149 2,581.0%   
Low Rs2,63782 3,204.1%   
Sales per share (Unadj.) Rs354.284.1 420.9%  
Earnings per share (Unadj.) Rs39.8-18.3 -217.2%  
Cash flow per share (Unadj.) Rs42.9-6.7 -640.0%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.983.7 283.0%  
Shares outstanding (eoy) m84.7061.25 138.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.11.4 665.9%   
Avg P/E ratio x81.4-6.3 -1,290.5%  
P/CF ratio (eoy) x75.5-17.2 -438.0%  
Price / Book Value ratio x13.71.4 990.3%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2167,074 3,876.2%   
No. of employees `0004.72.8 170.8%   
Total wages/salary Rs m4,8301,449 333.3%   
Avg. sales/employee Rs Th6,387.01,874.1 340.8%   
Avg. wages/employee Rs Th1,028.3527.0 195.1%   
Avg. net profit/employee Rs Th717.1-407.7 -175.9%   
INCOME DATA
Net Sales Rs m30,0005,154 582.1%  
Other income Rs m728100 729.7%   
Total revenues Rs m30,7285,254 584.9%   
Gross profit Rs m4,190-766 -546.8%  
Depreciation Rs m263711 37.0%   
Interest Rs m01,503 0.0%   
Profit before tax Rs m4,655-2,881 -161.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m4571,771 25.8%   
Tax Rs m1,74417 10,381.0%   
Profit after tax Rs m3,368-1,121 -300.4%  
Gross profit margin %14.0-14.9 -93.9%  
Effective tax rate %37.5-0.6 -6,423.7%   
Net profit margin %11.2-21.8 -51.6%  
BALANCE SHEET DATA
Current assets Rs m16,7423,810 439.4%   
Current liabilities Rs m7,2028,365 86.1%   
Net working cap to sales %31.8-88.4 -36.0%  
Current ratio x2.30.5 510.4%  
Inventory Days Days52156 33.3%  
Debtors Days Days2167 30.9%  
Net fixed assets Rs m8,63514,480 59.6%   
Share capital Rs m84761 1,381.7%   
"Free" reserves Rs m19,222903 2,128.4%   
Net worth Rs m20,0695,127 391.4%   
Long term debt Rs m105,832 0.2%   
Total assets Rs m30,03819,433 154.6%  
Interest coverage xNM-0.9-  
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x1.00.3 376.6%   
Return on assets %11.22.0 570.9%  
Return on equity %16.8-21.9 -76.7%  
Return on capital %25.53.6 700.2%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m5281,539 34.3%   
Fx outflow Rs m7,193942 763.6%   
Net fx Rs m-6,665597 -1,116.0%   
CASH FLOW
From Operations Rs m2,360599 393.9%  
From Investments Rs m3,008-438 -686.9%  
From Financial Activity Rs m-5,108-303 1,687.9%  
Net Cashflow Rs m260-141 -184.2%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.6 1,700.0%  
FIIs % 23.8 1.3 1,830.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 23.6 65.3%  
Shareholders   102,036 10,259 994.6%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Down 0.7%

Jun 22, 2018 | Updated on Jun 22, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,420 (up 1.67%). The BSE HEALTHCARE Index is down by 0.74%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.67%) and GSK PHARMA (up 0.01%). The top losers include PFIZER (down 0.00%) and IPCA LABS (down 0.01%).

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5%

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS